In addition, a recent meta-analysis has enrolled 11 BC studies, with 2958 participants, concerning the use of HOXB13/IL17BR ratio in association with a worse outcome, particularly for (N-) patients [75]. The gene discussed is IL17RB; the disease is breast cancer.